Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (4063)	4/10/2000 10:23:00 PM
From: DaveAu	Read Replies (2) \| Respond to of 14101

Wolf, Thanks. I was just looking at the same site while looking for that conference. I still don't know where or when but at least I know that "Salvage" refers to what should be done when a patient fails standard therapy so it sounds like the right place to report on our study. If they passed 200 two months ago, we must be very close. DMX is always conservative with these things. They certainly didn't try to get anyone excited with the news release. All they said was "safe and easy to administer". WTHC about that. I want to know if it works. Here's a link to some results for GM-CSF which has been previously mentioned on this thread. It doesn't sound all that impressive. hiv.medscape.com Dave